# Steve E Kalloger

List of Publications by Year
in descending order

| 87 papers | 9,847 citations | 61857<br>43 h-index | 49773<br>87 g-index |
|---|---|---|---|
| 87 all docs | 87 docs citations | 87 times ranked | 13857 citing authors |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1 | *ARID1A* Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543. | 13.9 | 1,460 |
| 2 | Mutation of *FOXL2* in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729. | 13.9 | 706 |
| 3 | Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLoS Medicine, 2008, 5, e232. | 3.9 | 675 |
| 4 | Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cellâ€" and patient-derived tumor organoids. Nature Medicine, 2015, 21, 1364-1371. | 15.2 | 591 |
| 5 | Recurrent Somatic *DICER1* Mutations in Nonepithelial Ovarian Cancers. New England Journal of Medicine, 2012, 366, 234-242. | 13.9 | 401 |
| 6 | Amplification of *PVT1* Contributes to the Pathophysiology of Ovarian and Breast Cancer. Clinical Cancer Research, 2007, 13, 5745-5755. | 3.2 | 345 |
| 7 | Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. International Journal of Gynecological Pathology, 2010, 29, 203-211. | 0.9 | 332 |
| 8 | Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nature Genetics, 2016, 48, 758-767. | 9.4 | 287 |
| 9 | Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402. | 2.9 | 241 |
| 10 | Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology, 2008, 39, 1239-1251. | 1.1 | 231 |
| 11 | IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 2011, 17, 2538-2548. | 3.2 | 217 |
| 12 | A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2009, 33, 14-21. | 2.1 | 211 |
| 13 | Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS ONE, 2013, 8, e72162. | 1.1 | 200 |
| 14 | FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. American Journal of Surgical Pathology, 2011, 35, 484-494. | 2.1 | 183 |
| 15 | Reproducibility of histological cell type in high-grade endometrial carcinoma. Modern Pathology, 2013, 26, 1594-1604. | 2.9 | 167 |
| 16 | Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas. Neoplasia, 2008, 10, 1021-1027. | 2.3 | 158 |
| 17 | Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Gastroenterology, 2019, 157, 823-837. | 0.6 | 153 |
| 18 | Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum. American Journal of Clinical Pathology, 2010, 134, 835-845. | 0.4 | 152 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 19 | BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Modern Pathology, 2012, 25, 740-750. | 2.9 | 151 |
| 20 | High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. International Journal of Gynecological Pathology, 2010, 29, 343-350. | 0.9 | 146 |
| 21 | Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. American Journal of Surgical Pathology, 2010, 34, 984-993. | 2.1 | 143 |
| 22 | Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecologic Oncology, 2010, 116, 50-56. | 0.6 | 129 |
| 23 | IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathology, 2009, 22, 469-475. | 2.9 | 125 |
| 24 | Altered Gene Expression along the Glycolysisâ€"Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 135-146. | 3.2 | 121 |
| 25 | Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes and Cancer, 2008, 47, 481-489. | 1.5 | 116 |
| 26 | ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Modern Pathology, 2014, 27, 255-261. | 2.9 | 110 |
| 27 | Nucleic acid quantity and quality from paraffin blocks: Defining optimal fixation, processing and DNA/RNA extraction techniques. Experimental and Molecular Pathology, 2012, 92, 33-43. | 0.9 | 100 |
| 28 | Calculator for ovarian carcinoma subtype prediction. Modern Pathology, 2011, 24, 512-521. | 2.9 | 95 |
| 29 | Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases. International Journal of Gynecological Pathology, 2010, 29, 99-107. | 0.9 | 90 |
| 30 | Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle, 2013, 12, 1433-1449. | 1.3 | 78 |
| 31 | Histologic Artifacts in Abdominal, Vaginal, Laparoscopic, and Robotic Hysterectomy Specimens. American Journal of Surgical Pathology, 2011, 35, 115-126. | 2.1 | 74 |
| 32 | In-Depth Proteomics of Ovarian Cancer Ascites: Combining Shotgun Proteomics and Selected Reaction Monitoring Mass Spectrometry. Journal of Proteome Research, 2011, 10, 2286-2299. | 1.8 | 72 |
| 33 | Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutationâ€positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer, 2012, 118, 681-688. | 2.0 | 71 |
| 34 | Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1677-1686. | 1.1 | 70 |
| 35 | Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097. | 0.8 | 67 |
| 36 | Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. International Journal of Gynecological Pathology, 2012, 31, 499-506. | 0.9 | 65 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecologic Oncology, 2013, 128, 371-376. | 0.6 | 63 |
| 38 | Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy. Clinical Cancer Research, 2010, 16, 2852-2860. | 3.2 | 58 |
| 39 | Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Medicine, 2007, 5, 33. | 2.3 | 52 |
| 40 | The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Modern Pathology, 2013, 26, 1255-1263. | 2.9 | 52 |
| 41 | Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Modern Pathology, 2015, 28, 1383-1389. | 2.9 | 51 |
| 42 | The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clinical and Experimental Metastasis, 2012, 29, 239-252. | 1.7 | 50 |
| 43 | The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecologic Oncology, 2008, 108, 561-568. | 0.6 | 47 |
| 44 | Detection of Lung Perfusion Abnormalities Using Computed Tomography in a Porcine Model of Pulmonary Embolism. Journal of Thoracic Imaging, 2003, 18, 14-20. | 0.8 | 43 |
| 45 | S100A1 Expression in Ovarian and Endometrial Endometrioid Carcinomas Is a Prognostic Indicator of Relapse-Free Survival. American Journal of Clinical Pathology, 2009, 132, 846-856. | 0.4 | 42 |
| 46 | Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618. | 1.1 | 42 |
| 47 | Regulation of HSulf-1 Expression by Variant Hepatic Nuclear Factor 1 in Ovarian Cancer. Cancer Research, 2009, 69, 4843-4850. | 0.4 | 40 |
| 48 | Loss of switch/sucrose non–fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. Histopathology, 2020, 77, 46-54. | 1.6 | 39 |
| 49 | Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. Biopreservation and Biobanking, 2013, 11, 83-93. | 0.5 | 35 |
| 50 | Biomarker Expression in Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, 2011, 30, 366-371. | 0.9 | 34 |
| 51 | Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis. International Journal of Gynecological Pathology, 2013, 32, 529-535. | 0.9 | 34 |
| 52 | ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Human Pathology, 2014, 45, 1258-1268. | 1.1 | 34 |
| 53 | Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. International Journal of Molecular Sciences, 2011, 12, 1334-1358. | 1.8 | 33 |
| 54 | HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1495-1502. | 1.2 | 31 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 55 | Determinants of Quality of Life in Ovarian Cancer Survivors: A Pilot Study. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 708-715. | 0.3 | 30 |
| 56 | Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5{ 2016, 40, 1155-1164. | 2.1 | 30 |
| 57 | Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600. | 1.3 | 30 |
| 58 | Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002329. | 0.5 | 30 |
| 59 | HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. Oncotarget, 2015, 6, 33705-33719. | 0.8 | 28 |
| 60 | Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection. Aging Cell, 2019, 18, e13018. | 3.0 | 27 |
| 61 | Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 397-404. | 0.9 | 25 |
| 62 | HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology, 2012, 60, 547-553. | 1.6 | 25 |
| 63 | Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. International Journal of Gynecological Pathology, 2014, 33, 560-567. | 0.9 | 25 |
| 64 | Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Medicine, 2020, 9, 4004-4013. | 1.3 | 25 |
| 65 | Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Clinical Cancer Research, 2021, 27, 150-157. | 3.2 | 24 |
| 66 | Use of Mismatch Repair Immunohistochemistry and Microsatellite Instability Testing. American Journal of Surgical Pathology, 2012, 36, 560-569. | 2.1 | 23 |
| 67 | Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma. PLoS ONE, 2013, 8, e82406. | 1.1 | 22 |
| 68 | Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. Journal of Clinical Pathology, 2016, 69, 431-439. | 1.0 | 19 |
| 69 | siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 569-590. | 2.3 | 17 |
| 70 | Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. PLoS ONE, 2016, 11, e0153844. | 1.1 | 17 |
| 71 | CT-Directed Microcoil Localization of Small Peripheral Lung Nodules: A Feasibility Study in Pigs. Journal of Investigative Surgery, 2005, 18, 265-272. | 0.6 | 16 |
| 72 | Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?. Clinical Cancer Research, 2021, 27, 246-254. | 3.2 | 16 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 73 | Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication. Health Expectations, 2020, 23, 884-892. | 1.1 | 15 |
| 74 | Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Reports, 2021, 37, 109817. | 2.9 | 14 |
| 75 | A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. Journal of Pathology: Clinical Research, 2017, 3, 179-190. | 1.3 | 12 |
| 76 | Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264. | 2.1 | 11 |
| 77 | Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. Molecular Cancer Therapeutics, 2020, 19, 1889-1897. | 1.9 | 10 |
| 78 | Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. Cancer Medicine, 2021, 10, 1155-1165. | 1.3 | 9 |
| 79 | Dynamics of leukocyte telomere length in pregnant women living with HIV, and HIV-negative pregnant women: A longitudinal observational study. PLoS ONE, 2019, 14, e0212273. | 1.1 | 7 |
| 80 | Stroma vs epitheliumâ€enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. International Journal of Cancer, 2021, 148, 481-491. | 2.3 | 7 |
| 81 | Accelerating typeâ€specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (<scp>COSP</scp>) is a reliable highâ€throughput tool for case review. Histopathology, 2013, 63, 704-712. | 1.6 | 5 |
| 82 | Expression of Matrix Metalloproteinase-1 in Alveolar Macrophages, Type II Pneumocytes, and Airways in Smokers: Relationship to Lung Function and Emphysema. Lung, 2014, 192, 467-472. | 1.4 | 5 |
| 83 | Increased Cancer Risk in Younger Patients with Thyroid Nodules Diagnosed as Atypia of Undetermined Significance. Cureus, 2018, 10, e2348. | 0.2 | 4 |
| 84 | Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 719-726. | 1.4 | 3 |
| 85 | Tomographic Comparison of Ventilation Techniques for CT-Guided Thoracoscopic Staple Excision of Subcentimeter Lung Nodules. Journal of Investigative Surgery, 2006, 19, 185-191. | 0.6 | 1 |
| 86 | Temporal Dynamics of Genomic Alterations in a BRCA1 Germlineâ€"Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan. JCO Precision Oncology, 2018, 2, 1-8. | 1.5 | 1 |
| 87 | Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. Biomarker Insights, 2021, 16, 117727192110498. | 1.0 | 1 |